Gene Therapy Market
The Global Gene Therapy Market, valued at USD 9.0 billion in 2023, is set to soar to USD 42.46 billion by 2031, reflecting a robust CAGR of 21.4%.
WESTFORD, MA, UNITED STATES, October 11, 2024 /EINPresswire.com/ -- The global gene therapy market is experiencing rapid growth, driven by advances in genetic engineering and increasing investment in research and development. Key trends include a rising focus on rare and genetic disorders, expanding applications in oncology and chronic diseases, and significant collaborations between biotech firms and academic institutions to enhance therapeutic outcomes.
The need for improved gene therapies is anticipated to rise throughout the next ten years due to the expanding uses of genome editing in biotechnology and the growing use of gene modification in a range of treatments. Due to increased public awareness and knowledge, genetic testing is becoming increasingly important in preventative healthcare.
Get Comprehensive Insights into The Gene Therapy Market with A Detailed Sample Report PDF Free: https://www.skyquestt.com/sample-request/gene-therapy-market
Emergence of Kymriah and Bluebird Bio's Revolutionary Treatments
In August 2024, the FDA has approved Kymriah, a new gene therapy by Novartis for rare blood diseases. This could allow for better treatments for patients everywhere. It is expected that these changes will promote growth in the industry and stimulate further improvements over the next four or five years.
The quick development of some medicinal applications is demonstrated by the introduction of a revolutionary gene therapy for sickle cell disease by Bluebird Bio in July 2024. The escalation in research and development expenditure and collaboration in new domains by multinational companies is expected to influence the future of personalized medicine and support the growth of the worldwide gene therapeutics industry.
Novartis and Bluebird Bio's Latest Innovations Are Poised to Transform Healthcare
Kymriah was recently licensed by the FDA for rare blood conditions. This indicates that Novartis made an important announcement regarding gene therapy advancement in August 2024. Hence, it is highly possible that, due to this change, companies will focus on applications expansion and enhancements of therapeutic alternatives within the next decade leading to a rise in overall market size because such growth establishes a benchmark for upcoming drugs.
Yorktown Heights, NY - Bluebird Bio’s innovative gene approach to treating sickle cell disease makes rapid progress in genetic medicine (New York Times, July 2024). The finding is anticipated to have a massive impact on both gene therapy and healthcare in the coming years by resulting in massive Research and Development investments as well as global partnerships on research.
Ask for Free Customization: https://www.skyquestt.com/speak-with-analyst/gene-therapy-market
Gene Therapy Market Segmental Analysis
Global Gene Therapy Market is segmented on the basis of type, vector, therapeutic area, route of administration, delivery mode, and region.
By type, market is segmented into gene silencing, cell replacement, gene augmentation, other therapies.
By vector, market is segmented into viral vectors, and non-viral vectors.
By therapeutic area, market is segmented into Neurology, Oncology, Hepatology, and Other Therapeutic areas.
By route of administration, market is segmented into intravenous, and other routes of administration.
By delivery method, market is segmented into IN VIVO, and EX VIVO.
By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Recent Major Moves by Pfizer, BioNTech, GSK, and Roche are Shaping the Future of Gene Therapy
Recently, the global gene therapy market has experienced some remarkable updates. In September 2024, Pfizer and BioNTech revealed a partnership to investigate gene therapies for rare genetic diseases, capitalizing on their collective knowledge of mRNA technology. The news that GSK (GlaxoSmithKline) had invested in a new gene editing platform aimed at curing chronic diseases was first reported in October 2024. In addition, Roche bought a biotech firm specializing in CRISPR-based therapeutics in November 2024. Consequently, due to these developments, personalized therapy is supposed to proceed in great strides in the next years owing to heightened innovation, substantial market growth and enhanced availability of state-of-the-art therapeutics.
The report covers the following players:
• Novartis AG (Switzerland) • Biogen Inc. (US) • Gilead Sciences, Inc. (US) • Bristol-Myers Squibb (US) • Alnylam Pharmaceuticals, Inc. (US) • Sarepta Therapeutics, Inc. (US) • Amgen, Inc. (US) • Orchard Therapeutics PLC (UK) • F. Hoffmann-La Roche AG (Switzerland) • Jazz Pharmaceuticals PLC (Ireland) • uniQure N.V. (Netherlands) • Johnson & Johnson (US) • bluebird bio, Inc. (US) • BioMarin Pharmaceutical Inc. (US) • Krystal Biotech, Inc. (US) • Shanghai Sunway Biotech Co. Ltd. (China) • Sibiono Genetech Co. Ltd. (China) • Ferring B.V. (Netherlands) • Vertex Pharmaceuticals Incorporated (US) • Pfizer Inc. (US) • Sangamo Therapeutics, Inc. (US) • Regenxbio (US) • Ultragenyx Pharmaceutical Inc. (US) • MeiraGTx Holdings PLC (UK) • AnGes, Inc. (Japan)
Read Gene Therapy Market Report Today - https://www.skyquestt.com/report/gene-therapy-market
Transformative Innovations and Market Dynamics Shaping the Market
The industry is about to be transformed by advancements in gene therapy as a result of recent breakthroughs and smart partnerships. It is expected that in the next decade, personalized medicine will experience significant progress, with Novartis’ Kymriah and Bluebird Bio’s revolutionary therapies serving as benchmarks. Advances in gene therapy are exemplified by recent projects from Pfizer, BioNTech, GSK and Roche. The companies’ bold forays into gene therapy promise to usher an era of unprecedented treatment possibilities and market growth. Research, collaboration and technological advances will keep transforming this field as it affects healthcare delivery systems.
Related Reports:
Regenerative Medicine Market is growing at a CAGR of 27.2% in the forecast period (2024-2031)Cancer Gene Therapy Market is growing at a CAGR of 20.42% in the forecast period (2024-2031)
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Visit Our Website: https://www.skyquestt.com/
Mr. Jagraj SinghSkyquest Technology Consulting Pvt. Ltd.+1 351-333-4748email us hereVisit us on social media:LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
You just read:
News Provided By
October 11, 2024, 13:07 GMT
EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above. Originally published at https://www.einpresswire.com/article/750970024/advances-in-genetic-engineering-driving-gene-therapy-market-at-21-4-cagr-by-2031
